THE European Medicines Agency
has approved Takeda
Pharmaceuticals’ Adcetris
(brentuximab vedotin) for the
treatment of relapsed or refractory
Hodgkin lymphoma and relapsed
or refractory systemic anaplastic
large cell lymphoma.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jun 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jun 11
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.